Trumps Hydroxychloroquine VS. Medias Preferred Remdesivir
Washington (Kirkland) nursing home: No hydroxychloroquine, 35 deaths out of 120 residents Texas nursing home: Treatment WITH hydroxychloroquine, 1 death out of 135 residents #COVIDー19 #coronavirus https://t.co/l6i4dVrC2z — James Todaro, MD (@JamesTodaroMD) April 11, 2020 Treatment options for #COVID19 in USA: Hydroxychloroquine: - $0.63 per pill - generic - 11 US manufacturers Azithromycin: - $0.84 per pill - generic - 12 US manufacturers Remdesivir: - $1000 per pill - on-patent - 1 US manufacturer (Gilead)... — James Todaro, MD (@JamesTodaroMD) April 12, 2020 So interesting that small, non-randomized trials showing marginal benefit (68%) for Remdesivir is presented as "great hope" by the MSM, but much larger studies for Hydroxychloroquine and Azithromycin that prove 91% effectiveness mean nothing and are just "dangerous." — Mike Coudrey (@MichaelCoudrey) April 12, 2020